Richard Lake

Richard Lake is an Adjunct Professor in the Department of Pathology and Laboratory Science, part of the School of Biomedical Sciences at The University of Western Australia. His research focuses on the interplay between chemotherapy and immunotherapy in cancer treatment, particularly in mesothelioma. He leads multiple grants exploring immune checkpoint therapies, genetic modifiers of cancer, and biomarkers for treatment response.

Research Interests:

• Immune mechanisms in cancer therapy
• Mesothelioma pathogenesis and treatment
• Chemotherapy-induced immune modulation
• Genetic factors influencing asbestos-related diseases

His work contributes to UN Sustainable Development Goals related to health and well-being (SDG 3) through advancements in cancer immunotherapy.

Recent Research Trends: Articles emphasize biomarker discovery, immune checkpoint dynamics, and combination therapies. Key topics include clonal expansion of tumor-infiltrating lymphocytes, transcriptomic signatures for survival prediction, and genetic modifiers of mesothelioma latency.

Grants & Projects (selected):

• NHMRC-funded National Centre for Asbestos Related Diseases (2020–2025)
• Mesothelioma Applied Research Foundation: Immune checkpoint-tumor autoimmunity separation (2021–2024)
• Australian Cancer Research Foundation: Cancer genomics (2018–2021)

Labs/Teams: Collaborates with the ACRF Centre for Advanced Cancer Genomics and multiple interdisciplinary teams investigating mesothelioma and immunotherapy.